Cargando…

Author correction to “Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles” [Acta Pharmaceutica Sinica B 12 (2022) 1523–1533]

Detalles Bibliográficos
Autores principales:	Wu, Canhao, Xu, Qin, Wang, Huiyuan, Tu, Bin, Zeng, Jiaxin, Zhao, Pengfei, Shi, Mingjie, Qiu, Hong, Huang, Yongzhuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638520/ https://www.ncbi.nlm.nih.gov/pubmed/37969729 http://dx.doi.org/10.1016/j.apsb.2023.08.007

Ejemplares similares

Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles
por: Wu, Canhao, et al.
Publicado: (2022)

Author correction to ‘Approved HIV reverse transcriptase inhibitors in the past decade’ [Acta Pharmaceutica Sinica B 12 (2022) 1567–1590]
por: Li, Guangdi, et al.
Publicado: (2023)

Author correction to ‘Protective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models’ [Acta Pharmaceutica Sinica B 11(2021) 1903–1913]
por: Yu, Ziru, et al.
Publicado: (2023)

Author correction to ‘Protective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models’ [Acta Pharmaceutica Sinica B 11 (2021) 1903–1913]
por: Yu, Ziru, et al.
Publicado: (2023)

Author correction to “Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers” [Acta Pharmaceutica Sinica B 11 (2021) 355–372]
por: Jiang, Tingting, et al.
Publicado: (2022)

Author correction to ‘Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling’ [Acta Pharmaceutica Sinica B 12 (2022) 1198–1212]
por: Wu, Yunhao, et al.
Publicado: (2022)

Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858]
por: Lai, Fangfang, et al.
Publicado: (2023)

Author correction to ‘Up-regulation of glycolipid transfer protein by bicyclol causes spontaneous restriction of hepatitis C virus replication’ [Acta Pharmaceutica Sinica B 9 (2019) 769–781]
por: Huang, Meng-Hao, et al.
Publicado: (2020)

Erratum to “Identification of anti-Mycobacterium tuberculosis agents targeting the interaction of bacterial division proteins FtsZ and SepFe” [Acta Pharmaceutica Sinica B 13 (2023) 2056–2070]
por: Zhang, Hongjuan, et al.
Publicado: (2023)

Author correction to “Coordinated regulation of BACH1 and mitochondrial metabolism through tumor targeted self-assembled nanoparticles for effective triple negative breast cancer combination therapy” [Acta Pharmaceutica Sinica B 12 (2022) 3934–3951]
por: Yang, Xuan, et al.
Publicado: (2023)

Author correction to ‘Ablation of Akt2 and AMPKα2 rescues high fat diet-induced obesity and hepatic steatosis through Parkin-mediated mitophagy’ [Acta Pharmaceutica Sinica B 11 (2021) 3508–3526]
por: Wang, Shuyi, et al.
Publicado: (2023)

Author correction to ‘Cardamonin from a medicinal herb protects against LPS-induced septic shock by suppressing NLRP3 inflammasome’ [Acta Pharmaceutica Sinica B 9 (2019) 734–744]
por: Wang, Zhilei, et al.
Publicado: (2020)

Author correction to ‘Design, synthesis and biological evaluation of chalcone analogues with novel dual antioxidant mechanisms as potential anti-ischemic stroke agents’ [Acta Pharmaceutica Sinica B 9 (2019) 335–350]
por: Wang, Jiabing, et al.
Publicado: (2022)

Author correction to “A nanocleaner specifically penetrates the blood‒brain barrier at lesions to clean toxic proteins and regulate inflammation in Alzheimer’s disease” [Acta Pharmaceutica Sinica B 12, (2021) 4032–4044]
por: Lei, Ting, et al.
Publicado: (2022)

Author correction to “DNA damage repair promotion in colonic epithelial cells by andrographolide downregulated cGAS‒STING pathway activation and contributed to the relief of CPT-11-induced intestinal mucositis” [Acta Pharmaceutica Sinica B 12 (2022) 262–273]
por: Wang, Yuanyuan, et al.
Publicado: (2023)

Author correction to ‘Actively priming autophagic cell death with novel transferrin receptor-targeted nanomedicine for synergistic chemotherapy against breast cancer’ [Acta Pharmaceutica Sinica B 2019; 9(5):1061–1077]
por: Mei, Dong, et al.
Publicado: (2020)

Author correction to ‘TMEM16A inhibits angiotensin II-induced basilar artery smooth muscle cell migration in a WNK1-dependent manner’ [Acta Pharmaceutica Sinica B 11 (2021) 3994–4007]
por: Zheng, Huaqing, et al.
Publicado: (2023)

Author correction to ‘Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo’ [Acta Pharmaceutica Sinica B 11 (2021) 3950–3965]
por: Deng, Linglong, et al.
Publicado: (2023)

Remarks from Editor-in-Chief on the celebration of the 65th anniversary of Acta Biochimica et Biophysica Sinica
por: Ding, Jianping
Publicado: (2023)

Scientia Pharmaceutica, Autorenhinweise 2013
Publicado: (2013)

Scientia Pharmaceutica, Autorenhinweise 2015
Publicado: (2015)

Scientia Pharmaceutica, Autorenhinweise 2016
Publicado: (2016)

Author correction to ‘Herbal formula BaWeiBaiDuSan alleviates polymicrobial sepsis-induced liver injury via increasing the gut microbiota Lactobacillus johnsonii and regulating macrophage anti-inflammatory activity in mice’ [Acta Pharmaceutica Sinica B 13 (2023) 1164–1179]
por: Fan, Xiaoqing, et al.
Publicado: (2023)

Acknowledgement to Reviewers of Scientia Pharmaceutica in 2017
Publicado: (2018)

SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses
por: Shah, Masaud, et al.
Publicado: (2022)

The Successful Relaunch of Scientia Pharmaceutica Continues Achieving Success
por: Kubelka, Wolfgang, et al.
Publicado: (2011)

1523. Clinical Epidemiology of Children with Orbital Cellulitis
por: Sharma, Meghna, et al.
Publicado: (2019)

Inhibition of SARS-CoV-2 pseudovirus invasion by ACE2 protecting and Spike neutralizing peptides: An alternative approach to COVID19 prevention and therapy
por: Chen, Jiang, et al.
Publicado: (2021)

Lenalidomide downregulates ACE2 protein abundance to alleviate infection by SARS-CoV-2 spike protein conditioned pseudoviruses
por: Su, Siyuan, et al.
Publicado: (2021)

Screening and evaluation of anti-SARS-CoV-2 components from Ephedra sinica by ACE2/CMC-HPLC-IT-TOF-MS approach
por: Lv, Yanni, et al.
Publicado: (2021)

Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2
por: Neerukonda, Sabari Nath, et al.
Publicado: (2021)

A Simplified SARS-CoV-2 Pseudovirus Neutralization Assay
por: Donofrio, Gaetano, et al.
Publicado: (2021)

Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2
por: Ge, Shuai, et al.
Publicado: (2021)

Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells
por: Xiong, Hua-Long, et al.
Publicado: (2020)

Repositioning of histamine H(1) receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2
por: Ge, Shuai, et al.
Publicado: (2021)

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
por: Nie, Jianhui, et al.
Publicado: (2020)

Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents
por: Mei, Jie, et al.
Publicado: (2021)

Characterization of Proanthocyanidin Oligomers of Ephedra sinica
por: Orejola, Joanna, et al.
Publicado: (2017)

Actas
por: Cedrón, José Antonio
Publicado: (1986)

Actas /
Publicado: (1986)

Cannot write session to /tmp/vufind_sessions/sess_24vmm9sb0va07argh29ugi3gr0